NCT00500058 2017-07-26A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18GlaxoSmithKlinePhase 1 Completed24 enrolled
NCT00085904 2008-10-13Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or LymphomasGlaxoSmithKlinePhase 1 Completed12 enrolled